CA
TXG icon

Clearstead Advisors’s 10x Genomics TXG Stock Holding History

Clearstead Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307 Buy
+8
New +$210 ﹤0.01% 3069
2026
Q1 		– Sell
-187
Closed -$3.05K – 2818
2025
Q4 		$3.05K Sell
187
-1,724
-90% -$26K ﹤0.01% 2098
2025
Q3 		$22.3K Sell
1,911
-1,274
-40% -$16.6K ﹤0.01% 1598
2025
Q2 		$36.9K Buy
3,185
+1,694
+114% +$15.4K ﹤0.01% 1389
2025
Q1 		$13K Buy
1,491
+224
+18% +$2.82K ﹤0.01% 1543
2024
Q4 		$18.2K Sell
1,267
-125
-9% -$1.97K ﹤0.01% 1418
2024
Q3 		$31.4K Buy
1,392
+125
+10% +$2.58K ﹤0.01% 1304
2024
Q2 		$24.6K Buy
+1,267
New +$33.2K ﹤0.01% 1322
2022
Q2 		– Sell
-8
Closed -$1K – 1454
2022
Q1 		$1K Hold
8
– – ﹤0.01% 1330
2021
Q4 		$1K Hold
8
– – ﹤0.01% 1223
2021
Q3 		$1K Hold
8
– – ﹤0.01% 1249
2021
Q2 		$2K Hold
8
– – ﹤0.01% 1088
2021
Q1 		$1K Hold
8
– – ﹤0.01% 1079
2020
Q4 		$1K Buy
+8
New +$1.16K ﹤0.01% 959

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Advisors's TXG Position: Q2 2026 in Review

Clearstead Advisors opened a new position in 10x Genomics (TXG) in Q2 2026: 8 shares worth $307. The stake represents ﹤0.01% of the portfolio and ranks #3069 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in TXG as recently as Q4 2025.

Clearstead Advisors first reported a position in TXG in Q4 2020 and has held it in 14 quarters since. The position peaked at $36.9K in Q2 2025. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Clearstead Advisors held 8 shares of 10x Genomics worth $307 as of Q2 2026.
  • 10x Genomics was a new Clearstead Advisors position in Q2 2026.
  • 10x Genomics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3069 holding.
  • Clearstead Advisors first reported a position in 10x Genomics in Q4 2020 and has held it in 14 quarters since.
  • Clearstead Advisors's 10x Genomics position peaked at $36.9K in Q2 2025.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.